Aurobindo Arm TheraNym Biologics To Invest Up To $175 Mn For New Manufacturing Facility

The investment follows the signing of an additional product schedule under an existing contract manufacturing organization (CMO) agreement with Merck Sharp & Dohme Singapore Trading Pte. Ltd. (MSD).

Aurobindo Pharma’s subsidiary TheraNym Biologics plans to invest between $150 million and $175 million to establish a new greenfield manufacturing facility focused on biologics production, according to a regulatory filing. The project will be developed in Hyderabad.

The upcoming facility will house mammalian cell culture bioreactors with a total capacity of 60,000 litres, along with downstream purification infrastructure required for drug substance manufacturing. The site will be used for large-scale production of biologics under a contract manufacturing framework.

The investment follows the signing of an additional product schedule under an existing contract manufacturing organization (CMO) agreement with Merck Sharp & Dohme Singapore Trading Pte. Ltd. (MSD). The agreement expands an earlier partnership initiated in May 2024 for biological manufacturing services.

Under the arrangement, TheraNym Biologics will be responsible for constructing the facility, manufacturing drug substances, and supplying them to MSD in line with the agreed terms. The project is expected to strengthen the company’s position in the global biologics manufacturing segment.

Aurobindo Pharma stated that the expansion is part of its broader strategy to scale up its biologics capabilities and deepen long-term partnerships in contract manufacturing.

The investment also reflects rising global demand for biologics production capacity, particularly in mammalian cell culture-based manufacturing, which is widely used for complex therapeutic drugs.

Stay tuned for more such updates on Digital Health News